Biodesix Announces Receipt of CLIA Registration Number
Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .
254 Results
Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .
Biodesix announced today that Douglas E. Swan has joined the company as Vice President, Commercial Operations, reporting directly to David Brunel, CEO
Biodesix announces the U.S. commercial availability of VeriStrat.
Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.